Electrical plasmon injection in double-layer graphene heterostructures

It is by now well established that high-quality graphene enables a gate-tunable low-loss plasmonic platform for the efficient confinement, enhancement, and manipulation of optical fields spanning a broad range of frequencies, from the mid infrared to the Terahertz domain. While all-electrical detection of graphene plasmons has been demonstrated, electrical plasmon injection (EPI), which is crucial to operate nanoplasmonic devices without the encumbrance of a far-field optical apparatus, remains elusive. In this work, we present a theory of EPI in double-layer graphene, where a vertical tunnel current excites acoustic and optical plasmon modes. We first calculate the power delivered by the applied inter-layer voltage bias into these collective modes. We then show that this system works also as a spectrally-resolved molecular sensor.Comment: 10 pages, 6 figure

Magnetic hallmarks of viscous electron flow in graphene

We propose a protocol to identify spatial hallmarks of viscous electron flow in graphene and other two-dimensional viscous electron fluids. We predict that the profile of the magnetic field generated by hydrodynamic electron currents flowing in confined geometries displays unambiguous features linked to whirlpools and backflow near current injectors. We also show that the same profile sheds light on the nature of the boundary conditions describing friction exerted on the electron fluid by the edges of the sample. Our predictions are within reach of vector magnetometry based on nitrogen-vacancy centers embedded in a diamond slab mounted onto a graphene layer.Comment: 5 pages, 6 figure

Impact of structural defects on the performance of graphene plasmon-based molecular sensors

Graphene-based plasmonic devices are regarded to be suitable for a plethora of applications, ranging from mid-infrared to terahertz frequencies. In this regard, among the peculiarities associated with graphene, it is well known that plasmons are tunable and tend to show stronger confinement as well as a longer lifetime than in the noble-metal counterpart. However, due to the two-dimensional specificity of graphene, the presence of defects might induce stronger effects than in bulky noble metals. Here, we theoretically investigate the impact of structural defects hosted by graphene on selected figures of merit associated to localized plasmons, which are of key technological importance for plasmon-based molecular sensing. By considering an optimized graphene nanostructure, we provide a comparative analysis intended to shed light on the impact of the type of defect on graphene localized plasmons, that regards distinct types of defects commonly arising from fabrication procedures or exposure to radiation. This understanding will help industry and academia in better identifying the most suitable applications for graphene-based molecular sensing.Comment: 8 pages, 5 figure

Nonlinear Hall effect as a local probe of plasmonic magnetic hot spots

Recently developed plasmonic nanostructures are able to generate intense and localized magnetic hot spots in a large spectral range from the terahertz to the visible. However, a direct measurement of the magnetic field at the hot spot has not been performed yet, due to the absence of magnetic field detectors that work at those high frequencies and that fit the hot-spot area. We propose to place a graphene ribbon in the hot spot of a plasmonic nanostructure driven by a laser beam, such that a current is generated due to both the magnetic field at the hot spot and the electric field of the laser. We demonstrate that a nonlinear Hall voltage, which can be measured by standard electrical means, builds up across the ribbon, making it possible to directly probe the magnetic field at the hot spot.Comment: 9 pages, 7 figure

Plasmomechanical Systems: Principles and Applications

AbstractExtreme confinement of electromagnetic waves and mechanical displacement fields to nanometer dimensions through plasmonic nanostructures offers unprecedented opportunities for greatly enhanced interaction strength, increased bandwidth, lower power consumption, chip‐scale fabrication, and efficient actuation of mechanical systems at the nanoscale. Conversely, coupling mechanical oscillators to plasmonic nanostructures introduces mechanical degrees of freedom to otherwise static plasmonic structures thus giving rise to the generation of extremely large resonance shifts even for minor position changes. This nanoscale marriage of plasmonics and mechanics has led to the emergence of a new field of study called plasmomechanics that explores the fundamental principles underneath the coupling between light and plasmomechanical nanoresonators. In this review, both the fundamental concepts and applications of plasmomechanics as an emerging field of study are discussed. After an overview of the basic principles of plasmomechanics, the active tuning mechanisms of plasmonic nano‐mechanical systems are extensively analyzed. Moreover, the recent developments on the practical implications of plasmomechanic systems for such applications as biosensing and infrared detection are highlighted. Finally, an outlook on the implications of the plasmomechanical nanosystems for development of point‐of‐care diagnostic devices that can help early and rapid detection of fatal diseases are forwarded

Resonant tunneling and the quasiparticle lifetime in graphene/boron nitride/graphene heterostructures

Tunneling of quasiparticles between two nearly aligned graphene sheets produces resonant current-voltage characteristics because of the quasiexact conservation of in-plane momentum. We claim that, in this regime, vertical transport in graphene/boron nitride/graphene heterostructures carries precious information on electron-electron interactions and the quasiparticle spectral function of the two-dimensional electron system in graphene. We present extensive microscopic calculations of the tunneling spectra with the inclusion of quasiparticle lifetime effects and elucidate the range of parameters (interlayer bias, temperature, twist angle, and gate voltage) under which electron-electron interaction physics emerges

Risk of COVID-19 after natural infection or vaccinationResearch in context

Summary: Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health

Risk of COVID-19 after natural infection or vaccinationResearch in context

Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation A Report From the GARFIELD-AF Registry

IMPORTANCE Congestive heart failure (CHF) is commonly associated with nonvalvular atrial fibrillation (AF), and their combination may affect treatment strategies and outcomes